1. Porsbjerg C, Melén E, Lehtimäki L, Shaw D. Asthma. Lancet 2023;401:858–873.

2. Barnes PJ, Adcock IM. How do corticosteroids work in asthma? Ann Intern Med 2003;139(5 Pt 1):359–370.

3. Murdoch JR, Lloyd CM. Chronic inflammation and asthma. Mutat Res 2010;690:24–39.

4. Meltzer EO, Kuna P, Nolte H, Nayak AS, Laforce C, P04073 Study Investigators. Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function. Eur Respir J 2012;39:279–289.

5. Pauwels RA, Löfdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405–1411.

6. Usmani OS, Singh D, Spinola M, Bizzi A, Barnes PJ. The prevalence of small airways disease in adult asthma: a systematic literature review. Respir Med 2016;116:19–27.

7. Scichilone N, Contoli M, Paleari D, et al. Assessing and accessing the small airways; implications for asthma management. Pulm Pharmacol Ther 2013;26:172–179.

8. Usmani OS. Small airways dysfunction in asthma: evaluation and management to improve asthma control. Allergy Asthma Immunol Res 2014;6:376–388.

9. Leach C, Colice GL, Luskin A. Particle size of inhaled corticosteroids: does it matter? J Allergy Clin Immunol 2009;124(6 Suppl):S88–S93.

10. Nam TH, Kang SY, Lee SM, Kim TB, Lee SP. Comparison of two pMDIs in adult asthmatics: a randomized double-blind double-dummy clinical trial. Tuberc Respir Dis (Seoul) 2022;85:25–36.

12. Kanniess F, Scuri M, Vezzoli S, Francisco C, Petruzzelli S. Extrafine beclomethasone/formoterol combination via a dry powder inhaler (NEXThaler®) or pMDI and beclomethasone monotherapy for maintenance of asthma control in adult patients: a randomised, double-blind trial. Pulm Pharmacol Ther 2015;30:121–127.

13. Morice AH, Peterson S, Beckman O, Osmanliev D. Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma. Int J Clin Pract 2007;61:1874–1883.

14. Kim SH, Kim TB, Kim SH, et al. Real-life clinical use of Symbicort ® maintenance and reliever therapy for asthmatic patients in Korea. Allergy Asthma Immunol Res 2018;10:88–94.

15. Carr TF, Altisheh R, Zitt M. Small airways disease and severe asthma. World Allergy Organ J 2017;10:20.

16. Cohen J, Postma DS, Douma WR, Vonk JM, De Boer AH, ten Hacken NH. Particle size matters: diagnostics and treatment of small airways involvement in asthma. Eur Respir J 2011;37:532–540.

17. Newman S, Salmon A, Nave R, Drollmann A. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 2006;100:375–384.

18. Leach C. Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol 1999;104:S250–S252.

19. Benfante A, Basile M, Battaglia S, Spatafora M, Scichilone N. The use of ICS/LABA (extra-fine and non-extra-fine) in elderly asthmatics. Ther Clin Risk Manag 2016;12:1553–1562.

20. Lavorini F, Pedersen S, Usmani OS, Aerosol Drug Management Improvement Team (ADMIT). Dilemmas, confusion, and misconceptions related to small airways directed therapy. Chest 2017;151:1345–1355.

21. Papi A, Mansur AH, Pertseva T, et al. Long-term fluticasone propionate/formoterol fumarate combination therapy is associated with a low incidence of severe asthma exacerbations. J Aerosol Med Pulm Drug Deliv 2016;29:346–361.

22. El Baou C, Di Santostefano RL, Alfonso-Cristancho R, et al. Effect of inhaled corticosteroid particle size on asthma efficacy and safety outcomes: a systematic literature review and meta-analysis. BMC Pulm Med 2017;17:31.

23. Nicolini G, Scichilone N, Bizzi A, Papi A, Fabbri LM. Beclomethasone/formoterol fixed combination for the management of asthma: patient considerations. Ther Clin Risk Manag 2008;4:855–864.

24. de Boer AH, Gjaltema D, Hagedoorn P, Frijlink HW. Can ‘extrafine’ dry powder aerosols improve lung deposition? Eur J Pharm Biopharm 2015;96:143–151.

25. Haughney J, Price D, Barnes NC, Virchow JC, Roche N, Chrystyn H. Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs. Respir Med 2010;104:1237–1245.

26. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56:588–599.

27. Scheuch G, Kohlhaeufl MJ, Brand P, Siekmeier R. Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv Drug Deliv Rev 2006;58:996–1008.

28. Alfieri V, Aiello M, Pisi R, et al. Small airway dysfunction is associated to excessive bronchoconstriction in asthmatic patients. Respir Res 2014;15:86.

29. Papi A, Corradi M, Pigeon-Francisco C, et al. Beclometasone- formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Lancet Respir Med 2013;1:23–31.

30. Rabe KF, Pizzichini E, Ställberg B, et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006;129:246–256.

31. Braido F, Arnaboldi E, Barile S, et al. BDP/FF NEXThaler to improve asthma control status in the real world: the NEWTON study. J Asthma Allergy 2023;16:1177–1186.

32. Dębowski T, Marko M, Rogala B, Majak P, Pawliczak R. Improvement of asthma control in adult patients using extrafine inhaled beclomethasone/formoterol fixed combination as maintenance therapy as well as maintenance and reliever therapy - CONTROL study. Pulm Pharmacol Ther 2024;84:102272.

33. Ställberg B, Naya I, Ekelund J, Eckerwall G. Real-life use of budesonide/formoterol in clinical practice: a 12-month follow-up assessment in a multi-national study of asthma patients established on single-inhaler maintenance and reliever therapy. Int J Clin Pharmacol Ther 2015;53:447–455.

34. Warren S, Taylor G, Smith J, Buck H, Parry-Billings M. Gamma scintigraphic evaluation of a novel budesonide dry powder inhaler using a validated radiolabeling technique. J Aerosol Med 2002;15:15–25.

35. Corradi M, Chrystyn H, Cosio BG, et al. NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma. Expert Opin Drug Deliv 2014;11:1497–1506.

36. Quanjer PH, Weiner DJ, Pretto JJ, Brazzale DJ, Boros PW. Measurement of FEF25–75% and FEF75% does not contribute to clinical decision making. Eur Respir J 2014;43:1051–1058.

37. Stanojevic S, Wade A, Stocks J, et al. Reference ranges for spirometry across all ages: a new approach. Am J Respir Crit Care Med 2008;177:253–260.

38. Postma DS, Brightling C, Baldi S, et al.; ATLANTIS study group. Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study. Lancet Respir Med 2019;7:402–416.

39. van der Wiel E, ten Hacken NH, Postma DS, van den Berge M. Small-airways dysfunction associates with respiratory symptoms and clinical features of asthma: a systematic review. J Allergy Clin Immunol 2013;131:646–657.

40. Pizzichini E, Brusselle G, Edwards D, et al. Run-in periods and treatment outcomes in asthma trials: a narrative review. Contemp Clin Trials Commun 2024;42:101382.